medigraphic.com

2024, Number 2

<< Back Next >>

Rev Mex Anest 2024; 47 (2)

Empirical use of cannabis to control chronic pain of musculoskeletal origin

Guevara-López UM, Elizarrarás-Rivas J, Ramírez-García SA, Hernández-Sosa V, De HA, González-Sánchez JÁ, Viguri-Castellanos RF

Language: Spanish
References: 23
Page: 96-101
PDF size: 319.67 Kb.


ABSTRACT

Introduction: the increasing acceptance of cannabinoids for therapeutic purposes has been linked to changes in legislation, high prevalence and ineffective control of chronic pain with conventional analgesics. Objective: determine the prevalence of chronic pain, the analgesic treatment modality with herbal therapies (cannabis) in adults in southeastern Mexico. Material and methods: a cross-sectional and ethnographic study was carried out on 267 people with chronic pain and regular use of herbal medicine for analgesic purposes. Hypothesis tests were carried out to evaluate differences between average values, age and pain intensity, comparing the use of cannabis with the type of pain, gender, algological diagnoses and comorbidities. Results: an association was observed between chronic pain: diabetes, hypertension, neoplasms in women, in older adults. 46% of the participants suffered from osteoarthritis and 20.9% had other diagnoses. The preferred modality for the topical administration of cannabis was tinctures in Mezcal or alcohol and to a lesser extent macerated in oils and inhalation. Conclusions: the findings do not allow cannabis to be considered as monotherapy for chronic pain in patients with chronic pain. However, they offer a promising field in the search for analgesic alternatives that avoid the chronic consumption of opiates or non-steroidal anti-inflammatory drugs (NSAIDs).


REFERENCES

  1. Abel EL. Marijuana: The first twelve thousand years. New York: Plenum Press; 1980.

  2. Bottorff JL, Bissell LJ, Balneaves LG, Oliffe JL, Capler NR, Buxton J. Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study. Harm Reduct J. 2013;10:2. doi: 10.1186/1477-7517-10-2.

  3. Adams RP. Identification of essential oils by ion trap mass spectroscopy. New York: Academic Press, Inc.; 1989.

  4. Sznitman SR, Zolotov Y. Cannabis for therapeutic purposes and public health and safety: a systematic and critical review. Int J Drug Policy. 2015;26:20-29. doi: 10.1016/j.drugpo.2014.09.005.

  5. Adler JN, Colbert JA. Clinical decisions. Medicinal use of marijuana polling results. N Engl J Med. 2013;368:e30. doi: 10.1056/NEJMclde1305159.

  6. Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013;24:511-516. doi: 10.1016/j.drugpo.2013.08.010.

  7. Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K et al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med. 2017;167:319-331. doi: 10.7326/M17-0155.

  8. Dueñas M, Salazar A, Ojeda B, Fernández-Palacín F, Micó JA, Torres LM, et al. A nationwide study of chronic pain prevalence in the general Spanish population: identifying clinical subgroups through cluster analysis. Pain Med. 2015;16:811-822. doi: 10.1111/pme.12640.

  9. Dominick CH, Blyth FM, Nicholas MK. Unpacking the burden: understanding the relationships between chronic pain and comorbidity in the general population. Pain. 2012;153:293-304. doi: 10.1016/j.pain.2011.09.018.

  10. Mücke M, Phillips T, Radbruch L, Petzke F, Hauser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3:CD012182. doi: 10.1002/14651858.CD012182.pub2.

  11. Cabrera-León A, Cantero-Braojos MÁ, Garcia-Fernandez L, Guerra de Hoyos JA. Living with disabling chronic pain: results from a face-to-face cross-sectional population-based study. BMJ Open. 2018;8:e020913. doi: 10.1136/bmjopen-2017-020913.

  12. Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556-63. doi: 10.1212/WNL.0000000000000363.

  13. Sainsbury B, Bloxham J, Pour MH, Padilla M, Enciso R. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis. J Dent Anesth Pain Med. 2021;21:479-506. Available in: https://doi.org/10.17245/jdapm.2021.21.6.479.

  14. Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328-335. doi: 10.1155/2014/754693.

  15. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press (US); 2017. ISBN-13: 978-0-309-45304-2.

  16. Rice J, Cameron M. Cannabinoids for treatment of ms symptoms: state of the evidence. Curr Neurol Neurosci Rep. 2018;18:50. doi: 10.1007/s11910-018-0859-x.

  17. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370:2219-2227. doi: 10.1056/NEJMra1402309.

  18. CONADIC. Informe sobre la Situación de la Salud Mental y el Consumo de Sustancias Psicoactivas. México: Autor; 2021. Disponible en: https://www.gob.mx/salud/conadic/documentos/informe-sobre-la-situacion-de-la-salud-mental-y-el-consumo-de-sustancias-psicoactivas-en-mexico-2021

  19. Reid MC, Eccleston C, Pillemer K. Management of chronic pain in older adults. BMJ. 2015;350:h532. Available in: https://doi.org/10.1136/bmj.h532

  20. Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Can Fam Physician. 2014;60:1083-1090.

  21. Koutouki K, Lofts K. Cannabis, reconciliation, and the rights of indigenous peoples: prospects and challenges for cannabis legalization in Canada. Alberta Law Rev. 2019;56:709-727. doi: 10.29173/alr2519.

  22. Vuckovic S, Srebro D, Vujovic KS, Vucetic C, Prostran M. Cannabinoids and pain: new insights from old molecules. Front Pharmacol. 2018;9:1259. doi: 10.3389/fphar.2018.01259.

  23. Kayode AA, Adrish S, Muhammad A, Amin R, Muhammad D, Rida Z et al. Therapeutic uses of medical cannabis: an overview of its functions in disease management. J Med Sci. 2023;23:32-39.




2020     |     www.medigraphic.com